Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress
In addition,
Details are as follows:
Oral Presentation Title: | Phase 3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization | |
Date: | Tuesday, April 16 | |
Time: | 3:40 p.m. E.T. | |
Panel Title: | COPD: The interplay of virus, bacterial pathogens and exacerbation, an opportunity for vaccines? | |
Date: | Wednesday, April 17 | |
Time: | 11:30 a.m. E.T. | |
Moderator: | Tod Merkel, Ph.D., Professor of Laboratory for Respiratory and Special Pathogens Division, Center for Biologics Evaluation and Research, Food and Drug Administration | |
Panelists: | Louis Fries III, M.D., Senior Vice President, Chief Medical Officer, Novavax Outi Vaarala, M.D., Ph.D., Senior Director, Respiratory Research, AstraZeneca Sanjay Sethi, Professor And Chief, Pulmonary, Critical Care and Sleep Medicine; Assistant Vice President for Health Sciences, The University at Buffalo | |
About ResVax™
ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant.
About
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
[email protected]
443-213-0506
Media
[email protected]
917-209-7163